Advertisement
Home »

Comparing Recombinant Human Rabies Monoclonal Antibody (Ormutivimab) with Human Rabies Immunoglobulin (HRIG) for Postexposure Prophylaxis: A Phase 3, Randomized, Double-Blind, Non-inferiority Trial.

May 22, 2023

ABOUT THE CONTRIBUTORS

  • Xiaoqiang Liu

    Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming, 650034, China.

    Yufeng Li

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China.

    Jingyu Li

    Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming, 650034, China.

    Jianmei Zhou

    Mile County Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, 652399, Yunnan Province, China.

    Jiangshu Guo

    Kaiyuan County Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, 661099, Yunnan Province, China.

    Yi Pu

    Gejiu County Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, 661099, Yunnan Province, China.

    Ya Jiang

    Mile County Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, 652399, Yunnan Province, China.

    Yaling Zhou

    Gejiu County Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, 661099, Yunnan Province, China.

    Zhiwei Jiang

    Statistics Department, Beijing Key Tech Statistical Consulting Co., Ltd., Beijing 100025, China.

    Qun Shu

    Statistics Department, Beijing Key Tech Statistical Consulting Co., Ltd., Beijing 100025, China.

    Cha Wang

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China.

    Jingke Wang

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China.

    Yu Zhao

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China.

    Wei Zhao

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China.

    Hui Wang

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China.

    Jingshuang Wei

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China.

    Hancheng Yu

    Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming, 650034, China.

    Jian Gao

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China. Electronic address: gaojian2989@163.com.

    Xiaona Li

    State Key Laboratory of Antibody Research & Development, NCPC New Drug Research and Development Co., Ltd., Shijiazhuang, 050000, China. Electronic address: 17732107187@163.com.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement